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Advances in genetic analysis have revealed new
complexities in the interpretation of genetic variants.
Correct assessment of a genetic variant relies on the
clinical context and knowledge of the underlying
biology. We outline four scenarios encountered in
genetic testing where careful consideration of the origin
of genetic variation is required for variant interpretation.through the opposite-sex parental lineage, giving theAdvances in DNA sequencing
Widespread availability of techniques for deep sequen-
cing of the human genome has accelerated the rate at
which the genetic basis of inherited and somatic condi-
tions is revealed. With massively parallel next-generation
sequencing, it is possible to accurately detect mutations
in small subsets of cells that were undetectable using
Sanger sequencing methods. In addition to mutations
associated with cancer, low-frequency somatic mutations
associated with local tissue proliferations and vascular
malformations typical of mosaic overgrowth syndromes
have recently been discovered. Extensive genomic ana-
lyses of a large number of patients with varying pheno-
types have exposed a complex relationship between
pathogenic variants identified in the context of inherited
and acquired conditions.Relationship between genotype and phenotype in
inherited and sporadic diseases
Deeper understanding of genotype–phenotype relation-
ships in inherited and somatic disease is enabling in-
novative clinical diagnostics for precision medicine, but* Correspondence: cpritch@uw.edu
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that may explain the genetic data. For example, classic
assumptions about inherited variants associated with
cancer predisposition have recently been challenged;
these assumptions include the need for multiple affected
generations, mutations in specific genes being related to
a specific spectrum of cancers, or that variants detected
in peripheral blood reflect only the germline. Cancers
with a strong gender-specific incidence may be passed
false impression that there is not a heritable syndrome
present [1]. It has also become clear that the genotype–
phenotype relationship with disease is broader than pre-
viously appreciated [2] and that variants detected in
blood may be of somatic origin [3].
Here, we describe four key areas where there is inter-
play between germline and somatic genetic mutations
that need be considered in relationship to an observed
phenotype for the correct variant interpretation in a
clinical context. The four areas we will address are: 1)
germline pathogenic variants discovered as part of
tumor-based testing, 2) tumor-based testing performed
for the purpose of clarifying germline mutation status, 3)
somatic mutations detected in peripheral blood as part
of cancer predisposition testing, and 4) mosaic muta-
tions detected in somatic overgrowth syndromes (Fig. 1).
Current guidelines for interpretation of inherited genetic
variants, such as from the American College of Medical
Genetics and Genomics and the Association for Molecu-
lar Pathology, do not adequately address clinical context
or somatic biological phenomena in the classification
schema. Furthermore, there are not yet widely accepted
guidelines for interpretation of variants identified in can-
cer. As the field moves forward, variant interpretation
schema that take into account the clinical context of thele is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Genetic variation attributable to distinct biological processes.
Variants detected by genetic testing may fall into at least four categories,
including inherited germline variants, post-zygotic somatic mosaic
mutations, lineage-restricted somatic mutations, such as in age-related
clonal hematopoiesis, and somatic mutations related to cancer (neoplasia)
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here, will allow more accurate variant assessment.
Germline origin for pathogenic variants identified
in tumor-based testing
In the course of tumor-based testing, germline cancer
predisposition mutations are more frequently identified
than in the general population because many cancers
have a heritable component. Furthermore, these muta-
tions may not be anticipated because of a lack of a
strong family history of cancer, sex-specific incidence of
certain neoplasms [1], or incomplete penetrance or
hypomorphic mutations [4].
Genomic interrogation of cancers has been undertaken
in various forms for decades, but the advent of quantita-
tive, single-nucleotide-resolution data of genetic aberra-
tions in cancer has been revolutionary. Recent data
reveal that pathogenic genetic variants identified within
cancer tissues are of germline origin in about 10 % of
both childhood and adult cancers unselected for family
cancer history [5, 6]. In these studies, loss of heterozy-
gosity or additional somatic mutations suggest that
germline mutations were significantly related to thedevelopment of cancer. These findings highlight that
one must consider the possibility of a germline origin
for pathogenic variants when evaluating cancer tissue,
even in the absence of a family history.
Variation in genetic mechanisms for a tumor
phenotype
Cancer tissue can provide useful information regarding
the origin of an observed phenotype and for inferring
germline genetic status. The best example of this is
Lynch syndrome, a cancer predisposition syndrome
caused by inherited mutations in mismatch repair genes.
Diagnostic algorithms have been developed to help iden-
tify individuals who are at risk of carrying a germline
mutation based on the tumor phenotype, and these indi-
viduals are typically referred for germline analysis of the
implicated genes if the screening test results are abnor-
mal. People with abnormal screening results can often
be classified with regard to their germline genetic risk of
Lynch syndrome, but a subset of patients cannot be clas-
sified using the commonly used methods and are gener-
ally treated as carriers of risk alleles that cannot be
currently identified (“Lynch-like” or “suspected Lynch”)
[7, 8]. Genomic analysis of cancer tissues in this sub-
group of patients has revealed that up to 70 % of these
unresolved cases are due to multiple somatic mutations
in mismatch repair genes that explain the screening re-
sults [8]. Identification of somatic mutations as the cause
of a positive Lynch-syndrome-screening test allows de-
escalation of ongoing cancer-surveillance programs in
these individuals and their families. Correct classification
of tumors into sporadic or Lynch syndrome-related is
important for future surveillance activities or selecting
effective therapies, regardless of the genetic origin of
their mismatch repair deficiency. This example high-
lights that genetic mechanisms for a tumor phenotype
may be varied, with implications for screening, diagnosis,
prognosis, and therapeutic management.
Somatic alteration of hematopoietic cells
Germline genetic testing for cancer predisposition genes
may reveal mutations that are not at the expected het-
erozygous or homozygous ratios for a germline variant.
When this is due to a population of cells that underwent
a somatic mutation during development (post-zygotic
mosaicism) it is relevant to cancer predisposition, so it is
important to identify such individuals when they present
for testing. Importantly, recent data suggest that a likely
explanation for many of these cases is the detection of
hematopoietic cells that have experienced a somatic al-
teration due to age [3] or chemotherapy exposure [9].
To complicate matters, sensitive screening methods cur-
rently in clinical use for non-cancer applications can de-
tect mutations from cancer cells that have shed cell-free
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nomena will become more commonplace as more indi-
viduals undergo evaluation using broad genetic testing
panels, in both clinical care and direct-to-consumer set-
tings. These observations reinforce the importance of in-
tegration of the genetic test results with the patient
phenotype, family history, and other factors when asses-
sing the significance of genetic variants.
Activating mutations resulting in somatic
overgrowth syndromes
Numerous syndromes are now described in which over-
growth of somatic tissues is a part of the spectrum of
the condition [10]. Application of sensitive genomic
techniques has revealed that the affected tissues in these
individuals often contain post-zygotic mosaic somatic al-
terations that are identical to those observed in cancer,
such as PIK3CA hotspot mutations. The identification of
activating mutations in the setting of somatic over-
growth syndromes not only is important for diagnosis
but may also have implications for targeted therapies
and requires selection of appropriate tissue sources in
addition to the analytical skills needed to arrive at a clin-
ically meaningful result.
Conclusions
We have briefly outlined four scenarios in which there is
overlap between genomic variants relevant to germline,
somatic, and invasive neoplastic disease. There is likely
to be more complexity that we have yet to uncover and
investigations into the contributions of epigenetic regu-
lation, host–microbiome interaction, or other research
avenues may reveal further relationships. In the coming
decade, as individual genomic analyses across a wide
variety of phenotypes become more common, the depth
of understanding of the described associations will in-
crease. To appropriately counsel clinicians and patients
on the interpretation of genetic testing results, labora-
tory providers and researchers must appreciate the rela-
tionship of an identified genetic variant, the clinical
context, and the potential biological processes at play.
Incorporation of these factors into professional genetic
variant interpretation guidelines in the coming years will
help increase recognition of the overlap between genetic
variants due to germline, somatic, or hematopoietic pro-
cesses and harmonize interpretation across a wide
spectrum of researchers and providers.
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